Redx Pharma Plc(REDX)

Description: Redx Pharma Plc, formerly Redx Pharma Ltd, is engaged in drug discovery, pre-clinical development and licensing. The Company is engaged in drug discovery across cancer, infection and autoimmune diseases. The Company has over two programs in its oncology research activity, Smoothened Hedgehog (SMO) and Bruton's Tyrosine Kinase (BTK), which has reached candidate nomination stage. The Company's oncology research activity also include Porcupine program, Colony Stimulating Factor-1 receptor (CSF-1) program, Indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibitor and Pan-Raf inhibitor. The Company's anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX003, is a class of antibiotic acting through the type II bacterial topoisomerases. It is also evaluating BTK inhibitor for immunological disorders.

---

Keywords: Cancer Disease Infectious Diseases Clinic Drug Discovery Oncology Infection Disorders Bacteria Oxygen Tyrosine Kinase Bacterial Infections Staphylococcus Aureus Mr Kinase Methicillin Erase Bruton's Tyrosine Kinase Immunological Disorders

---

Home Page: www.redxpharma.com

REDX Technical Analysis

Alderley Park
Macclesfield, SK10 4TG
United Kingdom
Phone: 44 16 2546 9900

---

Officers

Exchange: LSE

Country: UK

Currency: Pence sterling (p)